Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and
accounts for> 90% of cancers in the kidney. The disease encompasses> 10 histological and …

Kidney cancers have been extensively studied, and insights from an increased
understanding of tumor biology have led to increases in survival rates. Therapies aimed at …

The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging,
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …

PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …

Background Conditional survival estimates provide critical prognostic information for
patients with advanced renal cell carcinoma (aRCC). Efficacy, safety, and conditional …

Background The efficacy and safety of nivolumab plus cabozantinib as compared with those
of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not …

Purpose To report updated analyses of the phase III CheckMate 214 trial with extended
minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab …

ECOG performance status (PS) is a pivotal prognostic factor in a wide number of solid
tumors. We performed a meta-analysis to assess the role of ECOG PS in terms of survival in …

Background Nivolumab plus ipilimumab produced objective responses in patients with
advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus …

Background The role of radiotherapy in metastatic renal cell carcinoma is controversial. We
prospectively tested the feasibility and efficacy of radiotherapy to defer systemic therapy for …